The disclosure isn't related to Amgen's leading weight-loss drug, MariTide. Amgen says it expects to have the results of a midstage study of MariTide in patients with type 2 diabetes in the latter ...

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Amgen profits rise, next MariTide studies start by mid-year Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate ...

The company’s pipeline remains a key focus for investors and analysts alike. Amgen has several promising candidates in various stages of development, including: 1. MariTide: A potential game-changer ...

At the forefront of Amgen's growth strategy is its obesity program, headlined by MariTide. This potential blockbuster drug has garnered significant attention from analysts and investors alike. Cantor ...

Amgen has several promising candidates in various stages of development, including: 1. MariTide: A potential game-changer in the obesity treatment market, with phase II data expected in late 2024 ...